Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice video - https://m.weibo.cn/detail/4543339854046464
Really!!!!! You have a sense of humor.
AAPL stock is in the fourth split.
Hold and don't look around - The whole EV sector is up.This is the future of the car industry and that's what Mr. Market likes.
The same nonsense about TESLA as two years ago - or do you imagine that what we post here influences the market or traders?This is really hilarious.
NO WAY
Thank You - it's very,very slow
Someone else has problems with TDAmeritrade ?
TESLA - on way to NORD
Let's hope - this lack of communication from them does not do well and I do not understand what the problem is if they are so sure of their research.Anyway, I'm long.
Anyone else have problems with TD?
MS's upgrade was $ 20.50 a few days before the subscription. I wonder like many others if they didn't know about this $ 17 subscription.It's hard for me to believe they didn't know.How can we analyze this price if MS knew in advance of this subscription?
Will see
The same goes for me on TDA
USX has been the topic of several recent analyst reports. BofA Securities upgraded US Xpress Enterprises from a “neutral” rating to a “buy” rating and lifted their price target for the company from $7.00 to $9.00 in a research note on Wednesday, July 29th. ValuEngine downgraded US Xpress Enterprises from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. Stifel Nicolaus downgraded US Xpress Enterprises from a “buy” rating to a “hold” rating and cut their price objective for the company from $7.00 to $5.00 in a report on Friday, May 1st. Bank of America raised US Xpress Enterprises from a “neutral” rating to a “buy” rating and raised their price objective for the company from $7.00 to $9.00 in a report on Wednesday, July 29th. Finally, Zacks Investment Research raised US Xpress Enterprises from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a report on Thursday, June 4th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $8.25.
Several large investors have recently made changes to their positions in the company. FMR LLC acquired a new position in shares of US Xpress Enterprises in the 2nd quarter valued at about $1,685,000. Charles Schwab Investment Management Inc. lifted its stake in shares of US Xpress Enterprises by 39.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 64,165 shares of the company’s stock valued at $385,000 after purchasing an additional 18,006 shares during the period. Sei Investments Co. lifted its stake in shares of US Xpress Enterprises by 5.6% in the 2nd quarter. Sei Investments Co. now owns 595,552 shares of the company’s stock valued at $3,573,000 after purchasing an additional 31,324 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of US Xpress Enterprises in the 2nd quarter valued at about $101,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of US Xpress Enterprises by 370.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 434,112 shares of the company’s stock valued at $2,602,000 after purchasing an additional 341,873 shares during the period. 35.74% of the stock is currently owned by institutional investors.
Other research by Sorrento-
-THE ABIVERTINIB phase 3/PIVOTAL for NonSmall Cell Lung Cancer is pending possibly year end (srne website). Nsclc is a 11 billion market giving Sorrento a rich valuation up to $45/share alone.
- RTX while previously aimed at pain reduction for cancer patients has also been adopted for Covid pain management by alieviating symptoms.
Lori Ioannou for CNBC.
[ "The problem with Covid-19 is that the respiratory virus triggers an inflammation explosion in the nerves of the lungs that leads to fibrosis," says Sorrento's Ji. "It is called a cytokine storm, and that is what is killing people." As he explains, fibrosis causes scarring of the lungs and difficulty in breathing. RTX targets and blocks the nerves in the lungs that cause this response. "The key is to break this vicious cycle so the lungs can recover."
Dr. Harold Minkowitz, a physician at Memorial Hermann Medical Center in Houston, who has done research on vaccines and pain management since 1991, was involved in two clinical trials of RTX. One was to see how the drug worked on cancer patients. The other was to see if it helped patients with osteoarthritis.
"The results were pretty dramatic," he says. "After one injection, arthritic patients could walk and climb stairs. Cancer patients who had been immobilized in severe pain were able to walk and be pain free. One dose lasted for months."
As he explains, RTX works on specific nerve receptors that trigger inflammation and cause pain. ]
The global cystic fibrosis therapeutics market is expected to reach USD 13.9 billion by 2025, according to a new report by Grand View Research, Inc. Currently RTX is being evaulated for 3 separate indications which will have a triple digit impact on the stock. If initiated, the cystic fibrosis treatment will boost SRNE by $60/share alone.
I'm sorry to hear about your loss.
I have been here for over a year and a half and my investment at that time had nothing to do with CORONA virus research.
I've been in this stock for about two years.So long before this period in which the company develops CORONA-19 treatments or vaccines.Of course, a success on this research will create a formidable opportunity for investors, but at the same time a possible failure will create many financial problems for new entrants.Although the company has many other ongoing researches, many have forgotten about them.If you are here only for results related to CORONA virus my advice is to be prepared for a failure as well and to protect yourself.Personally, I believe in this success, but I am honestly much more positive about the results of previous research.
Certainly you are not longer than 3-4 months, which does not mean long. The problem with many of the "investors of the moment" is that many of them mix the notion of market with the casino. They enter for quick winnings and if possible as much older and many of them end up losing money.
With traders selling from this morning continuously with a profit of only a few cents? Hard to believe it will reach $ 3.
Buy and hold - all those who sold in the after trade yesterday felt today what it is like to lose money when you go after other sellers.If many of the traders do it in a certain way, it does not mean that it is the right way.Do your own research and then make the decision.
Canada and USA two extremely large markets for such vehicles -
NIO stock dilution explained -
The same kind of comments and analysis that TESLA went through 2-3 years ago. New loans, share issues, failure to reach the proposed level of production, all this made Tesla a perfect candidate for bankruptcy.Of course, NIO will not reach Tesla's market share, but let's not forget that NIO is probably in the world's largest market for EV sales or the company's latest moves - the BaaS program and so on.